With a market capitalization (market cap) of $8.09B — a measure of how much the company is worth — Spyre Therapeutics, Inc. ranks #1,045 among the 2,510 companies tracked, and 125th in Healthcare as of October 3, 2026. Shares trade at $93.19, up 3.63% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $7.9B | -30.35% | $93.19 |
| 2025 | Dec 31, 2025 | $11.34B | +708.02% | $32.76 |
| 2024 | Dec 31, 2024 | $1.4B | +200.37% | $23.28 |
| 2023 | Dec 29, 2023 | $467.09M | +1,488.32% | $21.52 |
Ranking figure $8.09B as of October 3, 2026.
Spyre Therapeutics, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $93.19 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $7.9B on October 2, 2026. See how the ranking works.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 64,056,442 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $5.97B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Spyre Therapeutics, Inc. (SYRE) is worth $8.09B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Spyre Therapeutics, Inc.’s book equity is about $715.24M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $8.09B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Spyre Therapeutics, Inc. ranks #1,045 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #125 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
| 2022 |
|---|
| Dec 30, 2022 |
| $29.41M |
| -90.62% |
| $11.25 |
| 2021 | Dec 31, 2021 | $313.48M | — | $118.75 |
|---|
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #1042 | Booz Allen Hamilton Holding Corporation BAH | $8.1B | -4.43% |
| #1043 | Ralliant Corp RAL | $8.1B | +3.39% |
| #1044 | Prosperity Bancshares, Inc. PB | $8.1B | +0.87% |
| #1046 | Kratos Defense & Security Solutions, Inc. KTOS | $8.08B | +0.58% |
| #1047 | Commerce Bancshares, Inc. CBSH | $8.06B | +0.82% |
| #1048 | AGCO Corporation AGCO | $8.03B | +2.50% |
Spyre Therapeutics, Inc.’s ranking market cap of $8.09B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 64,056,442. The historical market-cap series last observed $7.9B on October 2, 2026.
Over the past year, Spyre Therapeutics, Inc.’s market cap is up 42.79%, using historical market-cap records rather than today’s share count applied to past prices.
Spyre Therapeutics, Inc. (SYRE) shares trade at $93.19, up 3.63% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.